BioSpace News Archive

Increased cultivation capacity will enhance the Company’s ability to produce pharmaceutical grade psilocybin at scale

Welsh, Carson, Anderson & Stowe (WCAS), a leading private equity firm focused exclusively on the healthcare and technology industries, announced today that Dr. Adaeze Enekwechi will join the firm in June as an Operating Partner.

Foldax® , Inc. today announced the successful first-in-human use of its biopolymer Tria™ heart valve in surgically replacing a diseased mitral valve. The first case was performed by David Heimansohn, MD, at Ascension St. Vincent Hospital, Indianapolis, as part of a U.S. early feasibility research study.

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present at two upcoming investor conferences: Jefferies Virtual Healthcare Conference on June 2, 2021 at 2:30 p.m. EDT

Canadian Intellectual Property Office (CIPO) Issues Notice of Allowance for Canadian Patent Application supporting lead drug product candidate

ZYNLONTA™ Recently Approved as First and Only CD19-Targeted Antibody Drug Conjugate for Single-Agent Treatment for Adult Patients with Relapsed or Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL)

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has elucidated the mechanism of action of Adva-27a, the Company’s flagship anticancer drug candidate.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,013,785.

Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, reports financial results for the first quarter that ended March 31, 2021, along with an update on the company’s key developments, business operations and upcoming milestones.

Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced that Immutep CEO Marc Voigt has been invited to participate in the Jefferies Virtual Healthcare Conference, which is taking place from June 1st to 4th.